Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect
Roivant Sciences Ltd (NASDAQ:ROIV) is set to release its Q2 2025 earnings on Nov 12, 2024. The consensus estimate for Q2 2025 ...
Roivant Sciences (ROIV) Receives a Buy from TD Cowen
TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...
Seeking Alpha20d
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...
The Globe and Mail5h
Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises
The S&P 500 Index ($SPX) (SPY) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.69%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed ...
ETF Daily News7d
Gladstone Institutional Advisory LLC Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)
Roivant Sciences Ltd. has a 12 month low of $8.47 and a 12 month high of $13.06. The company has a market capitalization of $8.53 billion, a P/E ratio of 2.07 and a beta of 1.24.
Roivant Sciences (ROIV) Gets a Buy from Leerink Partners
In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...
ETF Daily News11d
Roivant Sciences Ltd. Announces Completion of Merger with Organon; Key Financial Details Revealed
Roivant Sciences Ltd., a prominent biopharmaceutical company listed on the NASDAQ under the ticker symbol ROIV, recently disclosed a significant development in its operations. As per an 8-K filing ...
Investing26d
JPMorgan reiterates price target, overweight on Roivant Sciences shares
On Wednesday, JPMorgan reaffirmed its confidence in Roivant Sciences (NASDAQ:ROIV) shares, maintaining an Overweight rating and a $16.00 price target on the stock. Following a recent meeting with ...
Investing21d
Leerink maintains outperform on Roivant with steady target
Leerink Partners maintained their Outperform rating on Roivant Sciences (NASDAQ:ROIV) with a steady price target of $17.00. The firm's analyst highlighted Roivant's executive incentive compensation ...
Roivant Sciences Ltd. (ROIV): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other promising ...
Investing20d
Roivant Sciences president sells $1.17 million in shares
Eric Venker, President and COO of Roivant Sciences Ltd. (NASDAQ:ROIV), recently executed a significant transaction involving the company's common shares. On October 21, Venker sold 100,000 shares ...
Yahoo Finance26d
Roivant Sciences (ROIV): High-Growth UK Stock with Innovative Drug Development Model
In this article, we are going to take a look at where Roivant Sciences (NASDAQ:ROIV) stands against other high growth UK stocks to invest in. According to a KPMG report, the United Kingdom’s GDP ...